CLAIMS

1. A pharmaceutical preparation for the treatment of schizophrenia and/or tardive dyskinesia, using an oil comprising eicosapentaenoic acid (EPA) and/or stearidonic acid (SA) in amounts of more than 20%, preferably more than 40% and very preferably more than 70% by weight of the total (preferably of the total unsaturated) fatty acids present and wherein the weight ratio of SA/EPA to n-6 EFAs present is not less than 3:1 and is preferably 4:1 or more, or n-6 EFAs are absent.

2. A method of treating, or a method of preparation of a medicament for treating, schizophrenia and/or tardive dyskinesia whereby EPA and/or SA is provided in the form of an oil containing more than 20% of said acid(s), preferably more than 40% and very preferably more than 70% by weight of the total (preferably total unsaturated) fatty acids present and wherein the weight ratio of SA/EPA to n-6 EFAs present is not less than 3:1 and is preferably 4:1 or more, or n-6 EFAs are absent.

3. A pharmaceutical preparation according to claim 1, or method according to claim 2, wherein the weight ratio of SA/EPA to any DHA present is not less than 3:1 and is preferably 4:1 or more.

4. A pharmaceutical preparation according to claim 1 or 3 or method according to claim 2 or 3 but for the treatment of depression .

5. A pharmaceutical preparation according to claim 1 or 3 or method according to claim 2 or 3 but for the treatment of Alzheimer's disease or other dementias.

6. Pharmaceutical preparation or medicament prepared as above which is suited to, or a method of treatment as above which employs, administration of 10mg to 100g, preferably 100mg to 20g, very preferably 500mg to 10g, EPA and/or SA daily.

7. Use of EPA and/or SA in the preparation of a medicament for the treatment of schizophrenia and/or tardive dyskinesia, or depression, or Alzheimer's disease or other dementias, in the form set out in claim 1, for the administration of 10mg to 100g, preferably 100mg to 20g, very preferably 500 mg to 10g, EPA and/or SA daily, with the weight ratio of SA/EPA to n-6 EFAs if present set out in claims 1 and 2 and desirably with the SA/EPA to DHA ratio set out in claim 3; and such treatment itself.